1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Panacea Biotec Limited

Panacea Biotec Limited

PANACEABIO.BO
Panacea Biotec LimitedIN flagBombay Stock Exchange
546.25
INR
-9.20
- -
33.44BMarket Cap
Panacea Biotec Limited
PANACEABIO.BO
(Bombay Stock Exchange)

Recent

price

546.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
184.67
115.93
99.34
83.26
112.19
106.62
85.77
93.6
73.85
87.7
100.84
107.63
74.6
90.11
91.51
- -
102.81
Revenue per Share
22.87
-33.58
-38.25
-18.31
-17.39
-2.99
-9.18
-12.08
6.16
-31.72
-24.11
176.05
-5.43
-0.19
-1.37
- -
-0.86
Basic EPS, GAAP
0.59
15.28
-16.95
-9.5
4.8
12.96
13.67
16.78
16.33
-6.1
13.88
-19.75
-75.66
-12.96
-12.71
- -
- -
Free Cash Flow per Basic Share
0.32
0.75
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
66.12
34.69
-3.69
-19.1
-33.84
28.25
19.22
9.38
15.43
-16.58
-40.47
135.63
129.95
129.71
128.66
- -
0.99
Book Value per Share
88.04
129.69
93.56
76.49
70.96
63.99
54.98
43.63
54.01
29.29
-40.31
140.38
132.92
130.97
129.04
- -
125.02
Tangible Book Value per Share
63
61
61
61
61
61
61
61
61
61
61
61
61
61
61
- -
62
Basic Weighted Avg Shares
11,679
7,101
6,085
5,100
6,872
6,531
5,254
5,733
4,523
5,372
6,176
6,592
4,569
5,519
5,591
6,398
6,398
Sales/Revenue/Turnover
17.26
-21.96
-27.95
-29.61
4.14
8.65
6.48
7.16
-24.74
7.83
5.95
-7.86
-23.12
-8.01
-10.86
-5.9
-5.9
Operating Margin (%)
773
771
860
711
672
733
680
585
550
441
461
438
391
367
348
331
331
Depreciation Expense
1,447
-2,057
-2,343
-1,121
-1,065
-183
-562
-740
377
-1,943
-1,477
10,783
-332
-12
-84
-54
-54
Net Income, GAAP
13.14
- -
- -
- -
- -
- -
- -
- -
15.85
- -
- -
25.6
363.53
201.9
- -
- -
79.7
Effective Tax Rate (%)
12.39
-28.96
-38.5
-21.99
-15.5
-2.8
-10.7
-12.9
8.34
-36.16
-23.91
163.57
-7.27
-0.21
-1.5
-0.84
-0.84
Profit Margin (%)
2,376
-150
-762
-4,540
-1,803
966
141
-1,307
-4,304
2,313
619
2,142
2,365
1,765
1,782
1,644
1,644
Working Capital
4,237
5,125
6,899
5,832
7,230
7,857
7,141
5,707
461
6,131
7,351
341
202
150
150
237
237
LT Debt
6,553
8,817
6,330
5,182
4,747
4,158
3,662
3,057
3,474
1,957
-2,317
8,737
8,401
8,382
8,306
8,289
8,289
Total Equity
12.27
- -
- -
- -
- -
- -
- -
- -
-8.45
- -
- -
-5.18
31.61
5.28
- -
- -
- -
Return on Invested Capital (%)
14.71
- -
- -
- -
- -
- -
- -
- -
12.61
- -
- -
169.46
-5.11
-0.44
- -
- -
- -
Return on Capital (%)
25.86
-65.22
- -
- -
- -
- -
-38.66
-84.44
49.64
- -
- -
- -
-4.09
-0.15
-1.06
-1.36
-1.36
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
229
- -
237
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
- -
61
Market Capitalization
24,862
23,034
18,429

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
5,330
- -
5,130
Cash, Cash Equivalents & STI
1,284
- -
1,347
Accounts Receivable, Net
762
- -
735
Inventories
1,953
- -
1,928
Total Current Liabilities
3,451
- -
3,487
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-75.91%
-96.45%
-0.21%
Free Cash Flow
-53.53%
-19.21%
-51.84%
Net Income, GAAP
-100.29%
-90.39%
-35.84%
Sales/Revenue/Turnover
1.48%
2.51%
14.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,292
1,430
1,505
1,292
5,519
2025
1,157
1,474
1,635
1,325
5,591
2026
1,667
1,411
1,652
1,668
6,398

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.79
-1.35
-0.37
- -
-0.19
2025
-2.59
0.77
0.74
-0.31
-1.37
2026
0.66
-2.27
0.65
0.08
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
YS Biopharma Co., Ltd. (YS)
AgeX Therapeutics, Inc. (AGE)
WPD Pharmaceuticals Inc. (WBIO.CN)
Bangi Inc. (BNGI)
Mindset Pharma Inc. (MSET.CN)
Kuros Biosciences AG (KURN.SW)
Business
Panacea Biotec Limited, a research-driven biotechnology company founded in 1984 and headquartered in New Delhi, India, with principal manufacturing facilities in Lalru, Punjab, and Baddi, Himachal Pradesh, develops, manufactures, and markets a broad portfolio of pharmaceutical formulations, vaccines, biosimilars, and nutraceuticals targeting oncology, nephrology, diabetology, gastroenterology, immunology, pain management, orthopaedics, organ transplantation, and pediatric care; key products include oncology therapies such as protein-bound paclitaxel (PacliAll), diabetes formulations like gliclazide (Glizid series), metformin (Metlong), and glimepiride (Betaglim), nephrology drugs including lanthanum carbonate, sevelamer, and valganciclovir, transplant medications like tacrolimus (PanGraf) and mycophenolic acid (Mycept), gastroenterology treatments such as Sitcom for haemorrhoids and aceclofenac combinations (Willgo CR), and an extensive range of WHO-prequalified vaccines encompassing polio, haemophilus influenzae type b, diphtheria-tetanus-polio combinations, DPT-hepatitis B-pentavalent (EasyFive), hexavalent (EasySix), dengue (Dengiall), influenza, tetanus, and pneumococcal vaccines. The company operates primarily in India across therapeutic segments for hospitals, physicians, and public health programs, with exports to developing markets, the United States, Germany, and UN agencies including UNICEF; it maintains offices in Mumbai and international subsidiaries such as the recently incorporated Panacea Biotec Inc. in Delaware, USA. Recent developments include a US$20 million long-term loan commitment from the US International Development Finance Corporation in 2024 to expand hexavalent vaccine EasySix production for global childhood immunization, additional UNICEF awards worth approximately US$5.20 million for bivalent oral polio vaccine supply in 2025, launches of toxin-free baby skincare (NikoMom) and infant milk substitute (Staart Prime) products by wholly-owned subsidiary Panacea Biotec Pharma Limited, appointment of Bal Krishan Saini as senior management personnel in operations and plant engineering effective November 2025, and an announced intent to acquire Power Gummies in 2025 to bolster nutraceutical offerings.